Arrowhead Pharmaceuticals, Inc. NASDAQ:ARWR

Arrowhead Pharmaceuticals stock price today

$19.81
+0.84
+4.48%
Financial Health
0
1
2
3
4
5
6
7
8
9

Arrowhead Pharmaceuticals stock price monthly change

-32.55%
month

Arrowhead Pharmaceuticals stock price quarterly change

-32.55%
quarter

Arrowhead Pharmaceuticals stock price yearly change

-38.90%
year

Arrowhead Pharmaceuticals key metrics

Market Cap
2.41B
Enterprise value
2.66B
P/E
-17.37
EV/Sales
9.58
EV/EBITDA
-19.55
Price/Sales
9.99
Price/Book
7.37
PEG ratio
0.76
EPS
-2.54
Revenue
N/A
EBITDA
-261.08M
Income
-289.25M
Revenue Q/Q
N/A
Revenue Y/Y
N/A
Profit margin
-55.51%
Oper. margin
-56.52%
Gross margin
11.64%
EBIT margin
-56.52%
EBITDA margin
N/A
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Arrowhead Pharmaceuticals stock price history

Arrowhead Pharmaceuticals stock forecast

Arrowhead Pharmaceuticals financial statements

Average Price Target
Last Year

$37

Potential upside: 86.77%

Based on estimate of 3 analysts
  • Analysts Price target

  • Financials & Ratios estimates

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR): Profit margin
Mar 2023 146.26M 48.67M 33.28%
Jun 2023 15.82M -102.94M -650.53%
Sep 2023 16.09M -109.67M -681.36%
Mar 2024 0 -125.3M
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR): Earnings per share (EPS)
2023-05-02 0.45 0.45
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR): Debt to assets
Mar 2023 891308000 426.20M 47.82%
Jun 2023 795856000 413.87M 52%
Sep 2023 765552000 478.39M 62.49%
Mar 2024 955150000 459.74M 48.13%
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR): Cash Flow
Mar 2023 -31.67M -36.06M 520K
Jun 2023 -21.44M -9.90M 1.80M
Sep 2023 -25.25M 30.50M 152K
Mar 2024 -92.37M -268.93M 430.77M

Arrowhead Pharmaceuticals alternative data

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR): Employee count
Aug 2023 397
Sep 2023 397
Oct 2023 397
Nov 2023 397
Dec 2023 397
Jan 2024 525
Feb 2024 525
Mar 2024 525
Apr 2024 525
May 2024 525
Jun 2024 525
Jul 2024 525

Arrowhead Pharmaceuticals other data

65.16% -0.55%
of ARWR is owned by hedge funds
68.11M -51.65K
shares is hold by hedge funds

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR): Insider trades (number of shares)
Period Buy Sel
Jan 2024 0 186217
Mar 2024 3000 40000
Apr 2024 0 6000
May 2024 0 1799
Jul 2024 0 9394
Dec 2024 0 61311
Transaction Date Insider Security Shares Price per share Total value Source
Sale
ANZALONE CHRISTOPHER RICHARD director, officer.. Common Stock 12,563 $19.59 $246,109
Sale
ANZALONE CHRISTOPHER RICHARD director, officer.. Common Stock 12,653 $20.52 $259,640
Sale
ANZALONE CHRISTOPHER RICHARD director, officer.. Common Stock 8,260 $21.74 $179,572
Sale
ANZALONE CHRISTOPHER RICHARD director, officer.. Common Stock 5,799 $22.12 $128,274
Sale
WADDILL WILLIAM D. director
Common Stock 3,747 $22.04 $82,584
Sale
GIVEN DOUGLAS B director
Common Stock 547 $22.04 $12,056
Sale
WADDILL WILLIAM D. director
Common Stock 3,748 $21.9 $82,081
Sale
GIVEN DOUGLAS B director
Common Stock 5,000 $21.9 $109,500
Sale
VAKIENER VICTORIA director
Common Stock 8,994 $21.91 $197,059
Sale
OLIVER TRACIE officer: Chief Commercial Officer
Common Stock 9,394 $25.28 $237,480
Patent
Application
Filling date: 5 Apr 2022 Issue date: 28 Jul 2022
Grant
Filling date: 31 May 2019 Issue date: 12 Jul 2022
Application
Filling date: 8 Jan 2020 Issue date: 30 Jun 2022
Application
Filling date: 10 Nov 2021 Issue date: 2 Jun 2022
Application
Filling date: 7 Feb 2022 Issue date: 26 May 2022
Application
Filling date: 3 Feb 2022 Issue date: 19 May 2022
Application
Filling date: 30 Jun 2021 Issue date: 21 Apr 2022
Application
Filling date: 23 Dec 2021 Issue date: 14 Apr 2022
Application
Filling date: 29 Nov 2021 Issue date: 24 Mar 2022
Application
Filling date: 17 Nov 2021 Issue date: 17 Mar 2022
Monday, 23 December 2024
businesswire.com
Thursday, 19 December 2024
businesswire.com
Wednesday, 11 December 2024
businesswire.com
Tuesday, 3 December 2024
businesswire.com
Monday, 2 December 2024
businesswire.com
Tuesday, 26 November 2024
seekingalpha.com
businesswire.com
businesswire.com
Monday, 18 November 2024
businesswire.com
businesswire.com
Monday, 4 November 2024
businesswire.com
Friday, 1 November 2024
businesswire.com
Monday, 14 October 2024
businesswire.com
Monday, 23 September 2024
businesswire.com
Tuesday, 3 September 2024
investopedia.com
Monday, 2 September 2024
businesswire.com
Wednesday, 14 August 2024
seekingalpha.com
Friday, 28 June 2024
investorplace.com
Tuesday, 25 June 2024
businesswire.com
businesswire.com
Monday, 24 June 2024
businesswire.com
Monday, 3 June 2024
businesswire.com
Friday, 31 May 2024
businesswire.com
Wednesday, 29 May 2024
businesswire.com
Tuesday, 28 May 2024
businesswire.com
Monday, 20 May 2024
https://www.defenseworld.net
businesswire.com
https://www.businesswire.com
Friday, 17 May 2024
seekingalpha.com
Tuesday, 14 May 2024
InvestorPlace
  • What's the price of Arrowhead Pharmaceuticals stock today?

    One share of Arrowhead Pharmaceuticals stock can currently be purchased for approximately $19.81.

  • When is Arrowhead Pharmaceuticals's next earnings date?

    Unfortunately, Arrowhead Pharmaceuticals's (ARWR) next earnings date is currently unknown.

  • Does Arrowhead Pharmaceuticals pay dividends?

    No, Arrowhead Pharmaceuticals does not pay dividends.

  • How much money does Arrowhead Pharmaceuticals make?

    Arrowhead Pharmaceuticals has a market capitalization of 2.41B and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 98.52% to 3.55M US dollars. Arrowhead Pharmaceuticals made a loss 599.49M US dollars in net income (profit) last year or $0.45 on an earnings per share basis.

  • What is Arrowhead Pharmaceuticals's stock symbol?

    Arrowhead Pharmaceuticals, Inc. is traded on the NASDAQ under the ticker symbol "ARWR".

  • What is Arrowhead Pharmaceuticals's primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of Arrowhead Pharmaceuticals?

    Shares of Arrowhead Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are Arrowhead Pharmaceuticals's key executives?

    Arrowhead Pharmaceuticals's management team includes the following people:

    • Dr. Christopher R. Anzalone Chief Executive Officer, Pres & Director(age: 56, pay: $1,610,000)
    • Mr. Kenneth A. Myszkowski Chief Financial Officer(age: 59, pay: $690,300)
    • Dr. Javier San Martin M.D. Chief Medical Officer(age: 60, pay: $673,570)
  • How many employees does Arrowhead Pharmaceuticals have?

    As Jul 2024, Arrowhead Pharmaceuticals employs 525 workers.

  • When Arrowhead Pharmaceuticals went public?

    Arrowhead Pharmaceuticals, Inc. is publicly traded company for more then 31 years since IPO on 16 Dec 1993.

  • What is Arrowhead Pharmaceuticals's official website?

    The official website for Arrowhead Pharmaceuticals is arrowheadpharma.com.

  • Where are Arrowhead Pharmaceuticals's headquarters?

    Arrowhead Pharmaceuticals is headquartered at 177 East Colorado Boulevard, Pasadena, CA.

  • How can i contact Arrowhead Pharmaceuticals?

    Arrowhead Pharmaceuticals's mailing address is 177 East Colorado Boulevard, Pasadena, CA and company can be reached via phone at +62 630 43400.

  • What is Arrowhead Pharmaceuticals stock forecast & price target?

    Based on 3 Wall Street analysts` predicted price targets for Arrowhead Pharmaceuticals in the last 12 months, the avarage price target is $37. The average price target represents a 86.77% change from the last price of $19.81.

Arrowhead Pharmaceuticals company profile:

Arrowhead Pharmaceuticals, Inc.

arrowheadpharma.com
Exchange:

NASDAQ

Full time employees:

525

Industry:

Biotechnology

Sector:

Healthcare

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in Phase 2b clinical trial to reduce production of angiopoietin-like protein 3; ARO-HSD, which is in Phase 1/2a clinical trial to treat liver diseases; ARO-ENaC, which is in a Phase 1/2a clinical trial to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; ARO-C3 for the treatment of complement-mediated disease that is in Phase 1/2a clinical trial; ARO-Lung2 for the treatment of chronic obstructive pulmonary disorder; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-XDH to treat uncontrolled gout; ARO-COV for the treatment of COVID-19 and other pulmonary-borne pathogens; and ARO-HIF2, which is in phase 1b clinical trial to treat clear cell renal cell carcinoma. It is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce the production of apolipoprotein A; and ARO-AMG1 for treating genetically validated cardiovascular targets. Arrowhead Pharmaceuticals, Inc. has a license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3 RNAi therapeutics for liver-expressed targets; and license and research collaboration agreement with Takeda Pharmaceuticals U.S.A., Inc. to develop RNAi therapeutic candidate as a treatment for liver disease. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.

177 East Colorado Boulevard
Pasadena, CA 91105

CIK: 0000879407
ISIN: US04280A1007
CUSIP: 04280A100